Mark Diagnostics News Today

BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British...

Marketresearch.biz reports that the Sepsis Diagnostics Market size is expected to be worth around USD 1.8 Bn by 2032 from USD 0.9 Bn in 2022, growing at a CAGR of 7.8% during the forecast period from 2023 to 2032.Overview of the Sepsis Diagnostics MarketThe Sepsis Diagnostics Market focuses on technologies and tests...

BioMark Diagnostics Inc. an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today it has received non-dilutive research funding from a...

DUBLIN--(BUSINESS WIRE)--Mar 29, 2024--

BioMark Diagnostics Inc. , an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization,...

/PRNewswire/ -- The "Syndromic Multiplex Diagnostic Markets with COVID-19 Impacts. Strategies and Trends, Forecasts by Syndrome (Respiratory, Sepsis, GI Etc.),...

/PRNewswire/ -- The "The World Market for Molecular Diagnostics, 12th Edition" report has been added to ResearchAndMarkets.coms offering. The World Market for...

/PRNewswire/ -- The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and...

BioMark Diagnostics Inc. a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today...

BioMark Diagnostics Inc. a leading liquid biopsy company focusing on metabolomics for the early diagnosis of hard to detect and treat cancers is pleased to announce today that its abstract has...